FindTrial
Sign In

The consistency assessment between HER2 status of Circulating tumor cell and tissue biopsy, correlation analysis between inconsistent results and disease progression

Consistency assessment of the HER2 status of circulating tumor cells with tissue biopsy and disease progression

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035015
Enrollment
Unknown
Registered
2020-07-27
Start date
2020-07-22
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Gold Standard:Immunohistochemistry or fluorescence in situ hybridization HER2 results by tissue biopsy
Index test:1.&#32
Number&#32
of&#32
circulating&#32
tumor&#32
cells
2.&#32
HER2&#32
status&#32
3.&#32
copy&#32
number&#32
variation&#32
in&#32

Sponsors

Guangzhou Red Cross Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Stage IV breast cancer with tumors greater than 5 cm in diameter; 2. Aged over 18 years; 3. HER2 status with tissue biopsy; 4. No coagulation dysfunction; 5. Life expectancy of more than three months; 6. ECOG performance 0-3.

Exclusion criteria

Exclusion criteria: Blood samples cannot be tested for CTC.

Design outcomes

Primary

MeasureTime frame
Circulating Tumor Cells;consistency;—

Countries

China

Contacts

Public ContactXiuwen Wang
wnwnwang@163.com+86 13751849212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026